Zevra Therapeutics to join the Nasdaq Biotechnology Index effective December 23, enhancing its visibility in the biotech sector.Quiver AI SummaryZevra Therapeutics, Inc. announced that it will be added...
Zevra Therapeutics announces organizational changes to enhance focus on rare disease therapeutics, consolidating leadership and streamlining operations.Quiver AI SummaryZevra Therapeutics, Inc. has announced...
Zevra Therapeutics announces CEO Neil McFarlane's participation in December investor events focused on rare diseases.Quiver AI SummaryZevra Therapeutics, Inc., a company focused on treating rare diseases,...
Zevra Therapeutics announces MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, now available via AmplifyAssist support program.Quiver AI SummaryZevra Therapeutics, Inc. announced...
Zevra Therapeutics: Q3 Earnings Snapshot